title: Low-dose continuous chemotherapy (LBCMVD-56) for refractory and relapsing lymphoma.
abstract: BACKGROUND
  Although lymphoid malignancies are generally chemosensitive, relapse is common. The use of high-dose therapy can make subsequent cytotoxic therapy intolerable. There is a need to develop regimens with low acute toxicity which are suitable for use in patients post-high dose therapy and following the failure of standard protocols.
  
  
  METHODS
  Twenty-six patients with lymphomas, fifteen of whom had received high-dose therapy, were treated with a novel regimen consisting of low-dose lomustine, chlorambucil, daily subcutaneous bleomycin, vincristine and methotrexate with dexamethasone on an eight-week cycle (LBCMVD-56). A median of three cycles was given.
  
  
  RESULTS
  The overall response rate at 12 weeks was 67% (21% complete remission (CR)) with a median overall survival of 13 months. A symptomatic response was seen in 72%. Previous high-dose therapy did not compromise the response rate. Toxicity was acceptable with grade 3-4 haematological toxicity seen in 27% of cycles, gastrointestinal toxicity seen in 11% and pulmonary toxicity seen in 8%. Thirty-one percent of patients required hospitalisation at some point during this treatment most commonly for neutropenic sepsis.
  
  
  CONCLUSIONS
  LBCMVD-56 is an inexpensive, outpatient-based regimen with low acute toxicity and a high response rate in this heavily pre-treated group of patients.
authors.affiliation: ICRF Department of Medical Oncology, St. Bartholomew's Hospital, London, UK.
authors.forename: J
authors.initials: J
authors.lastname: Shamash
authors.forename: J
authors.initials: J
authors.lastname: Walewski
authors.forename: J
authors.initials: J
authors.lastname: Apostolidis
authors.forename: A M
authors.initials: AM
authors.lastname: Wilson
authors.forename: J M
authors.initials: JM
authors.lastname: Foran
authors.forename: R K
authors.initials: RK
authors.lastname: Gupta
authors.forename: A Z
authors.initials: AZ
authors.lastname: Rohatiner
authors.forename: S M
authors.initials: SM
authors.lastname: Kelsey
authors.forename: T A
authors.initials: TA
authors.lastname: Lister
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D002699:Chlorambucil / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000473:pathology; D006760:Hospitalization; D006801:Humans; D007262:Infusions, Intravenous; D007279:Injections, Subcutaneous; D008130:Lomustine / Q000008:administration & dosage; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced; D018805:Sepsis / Q000139:chemically induced; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D001761:Bleomycin; D002699:Chlorambucil; D014750:Vincristine; D008130:Lomustine; D003907:Dexamethasone; D008727:Methotrexate